A new report out from Kalorama Information estimates that influenza vaccines sales rose by 13% to $3.1 billion in 2013. This figure brings the influenza vaccines market up from $2.8 billion in 2012, and back to the sort of levels we saw before the government’s stockpiling 2010 -as a result of this stockpiling, and perhaps over purchasing, the market dropped by 30% in 2011.
The report suggests that the return to form can in part be attributed to a stream of new quadrivalent products to hit the market in 2013. Prior to 2013 flu vaccine contain just one B strain, and with half of influenza-associated deaths in under 18s caused by influenza B, it’s no surprise that new quadrivalent vaccines from Medimmune, Sanfoi and GSK produced impressive sales.
The report also suggests that high vaccine uptake in 2013 also contributed to the increased market worth. This the authors attribute to both the early arrival of the 2013 flu season, and a heightened awareness of the effects and impact of influenza, though they recognise that amongst some of the most vulnerable are not being reached.
The CDC reports that the influenza costs the US approximately $750 million a year in deaths and preventable hospitalizations.
The report is available here.